GUIAS HIPERTENSION ARTERIAL.indb - Scc

Revista Colombiana de Cardiología
Febrero 2007
21. Teo K, Yusuf S, Sleight P, et al; ONTARGET/TRANSCEND Investigators. Rationale,
design, and baseline characteristics of 2 large, simple, randomized trials
evaluating telmisartan, ramipril, and their combination in high-risk patients: the
Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint
Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with
Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;
148: 52-61.
22. Gress T, Nieto J, Shahar E, et al, for the Atherosclerosis Risk in Communities
Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes
mellitus. N Engl J Med 2000; 342: 905-942.
23. Hypertension in Diabetes Study Group (HDS). Cardiovascular risk increases in
hypertensive, type 2 diabetics. J Hypertens 1993; 11: 319-325.
24. Stamler J, Vaccaro O, Neaton JD, for the MRFIT Study Group. Diabetes, other
risk factors and cardiovascular mortality across 12 years in screened men for
MRFIT. Diabetes Care 1993; 16: 434-444.
25. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel
blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension
in Europe Trial Investigators. N Engl J Med 1999; 340: 677-684.
26. Hansson L, Zanchetti A, et al. Effects of intensive blood pressure lowering and
low-dose aspirin on patients with hypertension: principal results of the Hypertension
Optimal Treatment (HOT) randomized trial: HOT Study Group. Lancet
1998; 351: 1755-1762.
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of
macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ 1998; 317: 703-713.
28. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus:
blood pressure goals, choice of agents, and setting priorities in diabetes care.
Ann Intern Med 2003; 138: 593-602.
29. European Society of Hypertension-European Society of Cardiology Guidelines
Committee. 2003 European Society of Hypertension-European Society of Cardiology
guidelines for the management of arterial hypertension. J Hypertens
2003; 21: 1011-1053.
30. Chobanian AV, Bakris GL, Black HR, et al, and the National High Blood Pressure
Education Program Coordinating Committee. The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure. The JNC 7 report. JAMA 2003; 289: 2560-2572.
31. American Diabetes Association. Standards of medical care for patients with DM.
Diabetes Care 2005; 28: S4-S24.
32. American Diabetes Association. Treatment of hypertension in adults with diabetes.
Diabetes Care 2003; 26: S80-82.
33. Dillon JJ. The quantitative relationship between treated blood pressure and
progression of diabetic renal disease. Am J Kidney Dis 1998; 22: 798-802.
34. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of
diabetic nephropathy. BMJ 1982; 285: 685-688.
35. Lewis EJ, Hunsicker LG, Bain RD, et al. The effect of angiotensin-convertingenzyme
inhibition on diabetic nephropathy. The Collaborative Study Group. N
Engl J Med 1993; 329: 1456-1462.
36. Viberti G, Mogensen C, Groop L, et al. Effect of Captopril on progression to
clinical proteinuria in patients with insulin-dependent diabetes mellitus and
micro-albuminuria. European Microalbuminuria Captopril Study Group. JAMA
1994; 271: 275-279.
37. Laffel LM, McGill JB, Gans DJ. The benefical effect of angiotensin converting
enzyme inhibition with captopril on diabetes nephropathy in normotensive IDDM
patients with microalbuinuria. North American Microalbuminuria Study Group.
Am J Med 1995; 99: 497-504.
38. Mathiesen ER, Hommel E, Hansen HP, et al. Randomized controlled trial of long
term efficacy of captopril on preservation of kidney function in normotensive
patients with insulin dependent diabetes and microalbuminuria. BMJ 1999;
319: 24-25.
39. The EUCLID Study Group Randomized placebo-controlled trial of lisinopril in
normotensive patients with insulin-dependent diabetes and normoalbuminuria
or microalbuminuria. Lancet 1997; 349: 1787-1792.
40. Barnett A, Bain S, Benter P, et al. Angiotensin-receptor blockade versus converting
enzyme inhibition in type 2 diabetes and nephropaty. N Engl J Med 2004; 357:
1952-61.
41. Brenner BM, Cooper ME, De Zeeuw, et al. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N
Engl J Med 2001; 345: 851-860.
Vol. 13 Suplemento 1
ISSN 0120-5633
261
42. Lewis EJ. Hunsicker LG, et al. Renoprotective effect of the angiotensina-receptor
antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N
Engl J Med 2001; 345: 851-860.
43. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with
enalapril on cardiovascular outcomes in patients with non insulin independent
diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
44. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality
in patients with diabetes in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;
359: 1004–1010.
45. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of
ramipril on cardiovascular and microvascular outcomes in people with diabetes
mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000;
355: 253-259.
46. PROGRESS Collaborative Study Group. Randomised trial of a perindopril-based
blood-pressure-lowering regimen among 6105 individuals with previous stroke
or transiet ischaemic attack. Lancet 2001; 358: 1033-1041.
47. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol
in patients with type 2 diabetes mellitus and hypertension: a randomized
controlled trial. JAMA 2004; 292: 2227-2236.
48. Tatti P, Pahor M, Byington RP, et al. Outcome results of Fosinopril versus Amlo-dipine
Cardiovascular Events Randomized Trial (FACET) in patients with hypertension
and NIDDM . Diabetes Care 1998; 21: 597-603.
49. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipine on renal
outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA
2001; 285: 2719-2728.
50. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on
size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54:
889-896.
51. Ruggenenti P, Fassi A, Ilieva AP, et al, for the Bergamo Nephrologic Diabetes
Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in
type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
52. Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril
on microalbuminuria reduction in hypertensive patients with type 2 diabetes:
the NESTOR Study. J Hypertens 2004; 22: 1613-1622.
53. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research
Group. Major cardiovascular events in hypertensive patients randomized to
doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment
to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
54. Matthews DR, Stratton IM, Aldington SJ, Colman RR, Kohner EM; UK Prospective
Diabetes Study Group. Risks of progression of retinopathy and vision loss
related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Arch Ophthalmol 2004; 122: 1631-1640.
55. Kalantarinia K, Siragy H. Elección de los fármacos antihipertensivos en pacientes
con diabetes. Angiotensina II y más allá. Current Diabetes Reports, Latin America
2003; 2: 138-145.
56. American Diabetes Association. Treatment of hypertension in adults with diabetes.
Diabetes Care 2003; 26 (Suppl 1): S80-S82.
57. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for
chronic kidney disease: Kidney Disease Outcome Quality Initiative. Am J Kidney
Dis 2002; 39 (suppl 2): S1-S246.
58. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update
for the management of patients with unstable angina and non-ST-segment
elevation myocardial infarction. J Am Coll Cardiol 2002; 40: 1366-1374.
59. Â-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol
in patients with acute myocardial infarction, I:mortality results. JAMA 1982; 247:
1707-1714.
60. The CAPRICORN Investigators. Effect of Carvedilol on outcome after myocardial
infarction in patients with left ventricular dysfunction: The CAPRICORN randomised
trial. Lancet 2001; 357: 1385-1390.
61. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker,
in patients with severe left ventricular dysfunction following myocardial infraction.
N Engl J Med 2003; 348: 1309-1321.
62. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation
and management of chronic heart failure in the adult. J Am Coll Cardiol 2001;
38: 2101-2113.
63. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:
metoprolol CR/XL randomized intervention trial in congestive heart failure(
MERIT-HF). Lancet 1999; 353: 2001-2007.